Epigenomics AG

About Epigenomics AG

Company Description

We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high medical need. Using blood as a liquid biopsy can improve patient access to cancer screening and thereby contribute to eradicate today’s deadliest cancer types such as colorectal, liver, and lung cancer. By leveraging our product pipeline and strong intellectual property, we aim to become a global leader in blood-based cancer detection.

Year founded

1998

Served area

Worldwide

Headcount

Headquarters

Geneststraße 5, 10829 Berlin – Germany

Filings & Publications

2021

Report	Q1	H1	Q3	FY
Consolidated Report	ENG GER	GER ENG	GER ENG	ENG
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

2020

Report	Q1	H1	Q3	FY
Consolidated Report				ENG
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

2022

Report	Q1	H1	Q3	FY
Consolidated Report	GER ENG
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date	Trading entity / Person	Association	Trade type	Volume
27.12.22	Ho, Dr. Selwyn	Board	Buy	4,200.00 €
23.12.22	von Prondzynski, Heino	Supervisory board	Buy	5,625.00 €
22.12.22	Lubenow, Dr. Helge	Supervisory board	Buy	1,934.20 €
22.12.22	Ahlers, Felix	Board	Other	22,000.00 €
20.12.22	von Prondzynski, Heino	Supervisory board	Buy	3,680.00 €
16.12.22	Lindenice GmbH	Board	Buy	7,400.00 €
16.12.22	IDAB Management GmbH	Supervisory board	Buy	7,400.00 €
16.12.22	Ho, Dr. Selwyn	Board	Buy	6,780.00 €
14.12.22	von Prondzynski, Heino	Supervisory board	Buy	40,000.00 €

Contact

Email address

First name

Last name

Phone number

Company

Your message

Yes, I have read, understand and agree to the Privacy Policy